Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Antimicrob. Chemother.

Title: The Journal of antimicrobial chemotherapy

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1460-2091

ISSN (Print): 0305-7453

Publication date (Electronic): Jun 01 2017

Volume: 72

Issue: 6

Affiliations

[1 ] Research Center of Infectious Diseases, Iaso Group Hospitals, Athens, Greece.

[2 ] Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.

[3 ] Central Laboratories, Iaso Group Hospitals, Athens, Greece.

[4 ] Department of Medicine-Infectious Diseases, Iaso General Hospital, Iaso Group, Athens, Greece.

Article

Publisher Item ID: 3077300

DOI: 10.1093/jac/dkx049

PubMed ID: 28369471

SO-VID: d0c627dd-842f-4212-803d-bb5c80dcb149

History

Data availability:

Comments

Comment on this article

scite_

Cited by 42

See all cited by